Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

The St. Louis surgical instrument maker has secured federal approval for a robotically-navigated device that aims to expand ...

The Pitt season premiere, "7:00 a.m.," ignores clichés in favor of a gritty, realistic, and uncompromising take on the ...

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, ...

Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S.

The daughter of former LPGA star Jane Park is dealing with a serious health issue and remains in the hospital. Park has been ...

Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

Cardiac Electrophysiology Institute Expands Catheter Ablation Access For Los Angeles Heart Rhythm Patients. <a href = target= ...

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year. ・The company expects adjusted EBITDA for 2026 to be between $100 million and ...

With widespread power outages, medicine shortages and rising food prices, experts say Cuba’s economy has never been worse, ...